Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the…
$69.00-1.20%
报价 2026-11-13
市值
$17.34B
EV
$10.79B
PE (TTM)
14.4x
预期 PE (FY2027)
18.6x
52 周区间距高点 -5.2%
$40.74$72.75
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EXELExelixis, Inc. | $17.34B | -1.2% | +10.1% | 96.4% | 14.4x | 11.5x | 15.1x | |
| MRNAModerna, Inc. | $90.38B | -3.4% | +19.2% | -12.6% | – | – | – | |
| BBIOBridgeBio Pharma, Inc. | $15.25B | +0.2% | +119.5% | 93.8% | – | – | – | |
| ALGNAlign Technology, Inc. | $11.86B | +0.8% | +2.6% | 68.7% | 25.0x | 14.9x | 20.1x | |
| TECHBio-Techne Corporation | $11.44B | +0.1% | +5.4% | 65% | 99.6x | 43.2x | 37.1x | |
| HALOHalozyme Therapeutics, Inc. | $11.43B | -0.4% | +36.3% | 78.2% | 29.3x | 20.9x | 15.2x | |
| BMRNBioMarin Pharmaceutical Inc. | $11.09B | +0.9% | +21.7% | 77.1% | 30.1x | 17.2x | 19.9x | |
| MDGLMadrigal Pharmaceuticals, Inc. | $9.93B | +0.5% | +66.8% | 94.1% | – | – | – | |
| CAICaris Life Sciences, Inc. | $6.61B | -3.8% | +37.6% | 69.7% | 80.6x | 47.7x | 57.9x | |
| 同行中位数 | – | – | +29.0% | 73.4% | 30.1x | 20.9x | 20.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。